Picture EBD Group BioTech Showcase 2021 Digital Event BTS2021 651x81
Organisation › Details

Mustang Bio Inc. (Nasdaq: MBIO)

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, to fund research and development, and to outlicense or bring the technologies to market. Mustang has partnered with top medical institutions to advance the development of CAR T therapies across multiple cancers, as well as a lentiviral gene therapy for XSCID. Mustang is registered under the Securities Exchange Act of 1934, as amended, and files periodic reports with the U.S. Securities and Exchange Commission (“SEC”). Mustang was founded by Fortress Biotech, Inc. (NASDAQ: FBIO). *


Period Start 2020-10-06 existent
Products Industry gene therapy
  Industry 2 CAR-T therapy product
Person Person Litchman, Manuel (Mustang Bio 201704– CEO before Arvinas + Novartis Pharmaceuticals Corp)
  Street 377 Plantation Street
  City 01605 Worcester, MA
  Tel +1-781-652-4500
    Address record changed: 2020-10-13
Basic data Employees n. a.
    * Document for �About Section�: Sirion Biotech GmbH. (10/6/20). "Press Release: Mustang Bio Licenses LentiBOOST Technology from Sirion Biotech for the Development of MB-207 Lentiviral Gene Therapy". Worcester, MA & Martinsried.
Record changed: 2020-10-14


Picture Kentro Design Corporate and Web Design Berlin 650x65px

More documents for Mustang Bio Inc. (Nasdaq: MBIO)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [iito] Made Without Love 650x80px

» top